Profile data is unavailable for this security.
About the company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
- Revenue in USD (TTM)0.00
- Net income in USD-21.89m
- Incorporated2014
- Employees14.00
- LocationImmix Biopharma Inc11400 West Olympic Blvd., Suite 200LOS ANGELES 90064United StatesUSA
- Phone+1 (310) 651-8041
- Websitehttps://immixbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incannex Healthcare Inc | 86.00k | -23.15m | 34.76m | 9.00 | -- | 5.27 | -- | 404.14 | -1.40 | -1.40 | 0.0052 | 0.3738 | -- | -- | -- | 9,555.56 | -- | -130.12 | -- | -148.24 | -- | -- | -26,922.09 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 37.17m | 43.00 | -- | 3.87 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 37.70m | 5.00 | -- | 3.37 | -- | 91.72 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Tonix Pharmaceuticals Holding Corp | 11.29m | -135.25m | 38.16m | 103.00 | -- | 0.4282 | -- | 3.38 | -52.81 | -52.81 | 0.6477 | 0.4768 | 0.0964 | 0.8291 | 4.05 | 109,621.40 | -115.46 | -59.46 | -134.34 | -65.92 | 20.74 | -- | -1,197.86 | -5,126.73 | 2.78 | -- | 0.0972 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Earth Science Tech Inc | 26.89m | 2.33m | 39.78m | 32.00 | 17.26 | 12.43 | 16.05 | 1.48 | 0.0076 | 0.0076 | 0.0878 | 0.0105 | 6.65 | 23.99 | 201.60 | 840,435.90 | 57.64 | -37.98 | 79.28 | -- | 71.30 | 63.87 | 8.67 | -15.48 | 1.09 | 3.34 | 0.0241 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| Fortress Biotech Inc | 62.50m | -57.53m | 43.27m | 186.00 | -- | 2.05 | -- | 0.6924 | -3.53 | -3.53 | 3.74 | 0.767 | 0.4502 | 2.16 | 6.70 | 336,026.90 | -88.98 | -52.50 | -142.15 | -99.46 | 60.55 | 63.17 | -197.64 | -236.94 | 1.06 | -9.66 | 1.31 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| United-Guardian, Inc. | 12.31m | 3.48m | 44.79m | 25.00 | 12.86 | 3.94 | 12.49 | 3.64 | 0.7585 | 0.7585 | 2.68 | 2.48 | 0.9684 | 4.74 | 7.44 | 492,490.80 | 27.41 | 29.84 | 31.57 | 34.39 | 53.43 | 55.31 | 28.30 | 28.79 | 6.02 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 45.14m | 100.00 | -- | -- | -- | 4.90 | -1.83 | -1.83 | 0.1979 | -0.7467 | 0.1416 | 1.67 | 4.67 | 92,100.00 | -130.68 | -55.75 | -174.03 | -78.33 | 74.08 | -- | -922.81 | -754.94 | 1.22 | -10.16 | 3.82 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| SCYNEXIS Inc | 8.57m | -36.44m | 45.16m | 29.00 | -- | 0.7715 | -- | 5.27 | -0.756 | -0.756 | 0.177 | 1.54 | 0.0692 | -- | 3.61 | 295,379.30 | -29.44 | -30.02 | -35.54 | -36.35 | -71.42 | -- | -425.41 | -86.76 | -- | -- | 0.1843 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -21.89m | 46.12m | 14.00 | -- | 2.63 | -- | -- | -0.8536 | -0.8536 | 0.00 | 0.6387 | 0.00 | -- | -- | 0.00 | -92.58 | -- | -114.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 49.87m | 137.00 | -- | 1,839.01 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| BGM Group Ltd | 29.87m | -7.86m | 50.59m | 298.00 | -- | 1.15 | -- | 1.69 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Aadi Bioscience Inc | 25.07m | -61.69m | 56.20m | 53.00 | -- | 0.8149 | -- | 2.24 | -2.29 | -2.29 | 0.9285 | 2.80 | 0.2225 | 0.696 | 4.09 | 281,685.40 | -54.75 | -50.25 | -65.27 | -56.15 | 87.39 | -- | -246.06 | -473.97 | 4.54 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
Data as of Nov 22 2024. Currency figures normalised to Immix Biopharma Inc's reporting currency: US Dollar USD
15.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 30 Sep 2024 | 1.12m | 4.09% |
| Bleichroeder LPas of 30 Sep 2024 | 850.00k | 3.10% |
| Cable Car Capital LLCas of 30 Sep 2024 | 796.10k | 2.90% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 698.54k | 2.55% |
| Lynwood Capital Management, Inc.as of 31 Mar 2024 | 405.00k | 1.48% |
| Geode Capital Management LLCas of 30 Sep 2024 | 150.08k | 0.55% |
| Next Edge Capital Corp.as of 30 Jun 2024 | 85.00k | 0.31% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 84.31k | 0.31% |
| RBC Capital Markets LLC (Investment Management)as of 30 Sep 2024 | 84.00k | 0.31% |
| Tocqueville Asset Management LPas of 30 Sep 2024 | 43.30k | 0.16% |
More ▼
Data from 31 Mar 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
